ANL vs AZN: fair value comparison
Adlai Nortye Group Ltd. and AstraZeneca PLC · Updated 2026-10-19
ANL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ANL currently ranks higher by quality score.
| ANL | AZN | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $11.03 | $165.41 |
| 12-month range | $0.88–$16.60 | $155.62–$209.48 |
| Rank by discount to fair value | — | #1 of 108 Healthcare |
| Rank by quality score | #94 of 301 Healthcare | #95 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ANL fair value analysis · AZN fair value analysis